Enleofen is a cutting-edge brand that is revolutionizing the treatment of fibro-inflammatory diseases. Founded as a spin-out from NHCS, SingHealth, and Duke-NUS Medical School, Enleofen is focused on developing new anti-fibrotic therapies. Their expertise lies in targeting the IL-11 pathway, which is a crucial driver of fibrogenesis, organ dysfunction, and inflammation in various fibrotic diseases.

Enleofen's approach is rooted in patient-based discovery, utilizing a therapeutic development strategy based on relevant biology. Their therapeutics are not only innovative but also safe and highly effective, addressing the most pressing healthcare challenges faced today. With a strong foundation of extensive safety studies and extensive human genetic data supporting their drug safety, Enleofen boasts an impressive patent portfolio.

With Enleofen, you can expect groundbreaking advancements in the field of fibro-inflammatory disease treatment. They are at the forefront of medical innovation, working tirelessly to transform the lives of those affected by these conditions. Contact Enleofen now to learn more about their groundbreaking solutions